SyntheMed To Submit PMA For Cardiac Anti-Adhesion Device This Month
This article was originally published in The Gray Sheet
Executive Summary
New Jersey biomaterials firm SyntheMed plans to submit a PMA this month for its Repel-CV adhesion barrier, which if approved will be the first anti-adhesion film in the U.S. intended specifically for cardiac use